Our journey
Our complex journey started in October 2019, and from that moment on, we committed to finding an innovative solution for our target with multiple sclerosis and oncology patients. We dove passionately into the topic to understand more about these diseases and then we completely immersed ourselves into the life of the people we got in touch with. We talked with them, we learned about empathy, and we tried to really understand their hidden and unmet needs: dealing with fatigue was one of them.
After 9 months of hard work here we are! 7 individuals with very different mindsets and from different backgrounds made into a real team. Scroll to learn a little bit more about us, our process and our corporate partner.
The starting point
How might we improve the quality of life of multiple sclerosis and cancer patients?
Our process
9 months of work are difficult to summarize. In our booth, you will find all the information you need about our final solution and its possible future, the science behind it, and our personas. If you want to know more about our process, trials and errors, you’re welcome to read our reports.
Meet the team!
We are 7 students from the University of Modena and Reggio Emilia and Politecnico di Milano. Together with our teaching assistants, Mario and Silvia, we are Team PoliMore.
Our corporate partner is Sanofi Genzyme Italy, the local specialty care business unit of Sanofi focusing on rare diseases, multiple sclerosis, oncology, immunology, and rare blood disorders. Sanofi Genzyme helps people with debilitating and complex conditions that are often difficult to diagnose and treat.
​
The branch dedicates to discovering and advancing new therapies and providing hope to patients and their families around the world. For over a decade, they have been working to develop novel treatments for multiple sclerosis. They also have a portfolio of medicines indicated across a variety of cancers.
​
The company was founded in 1981 and is based in Cambridge, Massachusetts. Genzyme was acquired by Sanofi in 2011, and has a presence in approximately 65 countries, with 17 manufacturing facilities and 9 genetic-testing laboratories.